SYMBIOTEC
Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited (SYMBIOTEC) financial statements and selected valuation metrics through 30 September 2026.
Key metrics
Price as of 2026-11-13
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What we see
- ✓Revenue grew 16% in the latest year — strong top-line momentum.
Quarterly results
Quarterly · ₹ Cr · click a figure for its source · Ctrl-click to pick several to share
| Metric | Jun 2026 | Sept 2026 |
|---|---|---|
| Sales | 218 | 280 |
| Operating expenses (approx.) | 173 | 188 |
| EBITDA | 45 | 92 |
| OPM % | 20.7% | 32.7% |
| Other income | 0.34 | 0.11 |
| Interest | 6 | 6 |
| Depreciation | 22 | 22 |
| Profit before tax | 18 | 64 |
| Tax % | 19.8% | 19.2% |
| Net profit | 14 | 52 |
| EPS (₹) | 2.24 | 8.20 |
1,234 from the company's filing1,234 calculated by BullKarma
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · click a figure for its source · Ctrl-click to pick several to share
| Metric | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| Sales | 716 | 752 | 869 | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 545 | 550 | 631 | Sign in free for the trailing twelve months |
| EBITDA | 171 | 202 | 238 | Sign in free for the trailing twelve months |
| OPM % | 23.9% | 26.9% | 27.4% | Sign in free for the trailing twelve months |
| Other income | 7 | 4 | 3 | Sign in free for the trailing twelve months |
| Interest | 7 | 16 | 25 | Sign in free for the trailing twelve months |
| Depreciation | 39 | 43 | 53 | Sign in free for the trailing twelve months |
| Profit before tax | 131 | 147 | 153 | Sign in free for the trailing twelve months |
| Tax % | 23.6% | 34.1% | 28.3% | Sign in free for the trailing twelve months |
| Net profit | 100 | 97 | 110 | Sign in free for the trailing twelve months |
| EPS (₹) | 18.00 | 17.39 | 19.10 | Sign in free for the trailing twelve months |
| Dividend payout % | — | — | — | Sign in free for the trailing twelve months |
1,234 from the company's filing1,234 calculated by BullKarma
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · click a figure for its source · Ctrl-click to pick several to share
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity capital | 11 | 11 | 13 |
| Reserves | 704 | 804 | 1,137 |
| Borrowings | 247 | 541 | 388 |
| Other liabilities | 333 | 224 | 243 |
| Total liabilities | 1,295 | 1,580 | 1,781 |
| Fixed assets (net) | 411 | 402 | 1,084 |
| CWIP | 208 | 568 | 64 |
| Investments | 4 | 1 | 4 |
| Inventories | 336 | 261 | 237 |
| Trade receivables | 126 | 176 | 198 |
| Cash & bank | 7 | 26 | 10 |
| Other assets | 203 | 145 | 183 |
| Total assets | 1,295 | 1,580 | 1,781 |
1,234 from the company's filing1,234 calculated by BullKarma
Cash flows
Annual · ₹ Cr · last column includes FCF · click a figure for its source · Ctrl-click to pick several to share
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from operating activity | 188 | 47 | 175 |
| Cash from investing | -206 | -307 | -227 |
| Cash from financing | 22 | 278 | 36 |
| Net cash flow | 3 | 19 | -16 |
| Free cash flow (OCF − Capex) | -22 | -261 | -51 |
Ratios
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| ROCE % | 14.4% | 12.0% | 11.6% |
| ROE % | 14.0% | 11.9% | 9.6% |
| PBT margin % | 18.3% | 19.6% | 17.6% |
| Cash conversion cycle | 190 | 306 | 202 |
| OCF / EBITDA % (3 years) | — | — | 67.0% |
| Debt / equity | 0.35 | 0.66 | 0.34 |
| Net debt / EBITDA | 1.40 | 2.55 | 1.59 |
| EBITDA / interest | 23.68 | 12.59 | 9.39 |
1,234 from the company's filing1,234 calculated by BullKarma